Another mechanism to permit wider availability of experimental agents is the "parallel track" policy (Federal
Register of May 21, 1990) developed by the U.S. Public Health Service in response to AIDS. Under this policy,
patients with AIDS whose condition prevents them from participating in controlled clinical trials can receive
investigational drugs shown in preliminary studies to be promising.
